Dr. Richard Riese is a physician-scientist with more than 20 years of experience in the biopharmaceutical industry and academic medicine. He brings experience across all phases of clinical development in a broad range of rare and immunologically-based diseases to the AlloVir management team. In his role at AlloVir, Dr. Riese leads the clinical development of the company’s investigational virus-specific T cell therapies and also leads the company’s safety monitoring and reporting.
Before joining AlloVir, Dr. Riese served as Chief Medical Officer at Synlogic Inc. and held Vice President positions in clinical development at Alnylam and Alexion. At Alexion, he served as Head of the Translational Clinical Sciences in the research unit responsible for the clinical development strategy of all compounds from discovery to proof-of-concept. Dr. Riese’s industry experience began at Pfizer, where he played a critical role in the development and regulatory approval of Xeljanz, the first janus kinase inhibitor approved for the treatment of patients with rheumatoid arthritis.
Dr. Riese received his MD and PhD from the Medical College of Wisconsin and his BS in Mathematics from the University of Wisconsin-Madison. He carried out his residency training in Internal Medicine and his fellowship training in Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital in Boston.